Obesity in the Elderly Diabetic Patient

Obesity and type 2 diabetes constitute major public health issues in modern societies worldwide. Their prevalence on a global scale is alarming, and efforts to control their spread represent a priority of the public health agenda (1). Obesity is clearly driving a parallel epidemic of associated chronic diseases in all age-groups, including type 2 diabetes, hyperlipidemia, hypertension, atherosclerosis, obstructive sleep apnea, and liver dysfunction. Considerable attention is currently being focused on the consequences of obesity in vulnerable populations at both ends of the age spectrum, namely in youth and in the elderly. Elderly people, defined as individuals >65 years of age, comprise a substantial and growing part of the population in developed countries. Current demographic data in Western societies report that 12–15% of the general population is over the age of 65 years, and this proportion is projected to reach 20–25% by the year 2030 (2). Moreover, in the last 2 decades, the rate of obesity has risen dramatically among older adults, independently of sex, race, and educational level (3). This obesity epidemic significantly affects the health status of the geriatric population, since excess body weight in the elderly also correlates strongly with chronic ill health, poor quality of life, functional decline, disability, and dependency (4). Conversely, evidence suggests that obesity in the elderly is probably not associated with the same risks as in younger individuals, while in certain aspects, can even be protective (5). Furthermore, the prevalence of underweight is higher among older adults, who are also more vulnerable to unintentional weight loss either as a result of illness, or due to the aging process itself. The objective of this article is to assess the benefits relative to risks of weight loss that may be attained in the geriatric population, with special reference to the elderly diabetic patient. …

[1]  Jaakko Tuomilehto,et al.  Determinants for the Effectiveness of Lifestyle Intervention in the Finnish Diabetes Prevention Study , 2008, Diabetes Care.

[2]  M. Schulze Determinants for the Effectiveness of Lifestyle Intervention in the Finnish Diabetes Prevention Study , 2008, Diabetes Care.

[3]  R. R. Wolfe,et al.  The danger of weight loss in the elderly , 2008, The journal of nutrition, health & aging.

[4]  A. Scheen,et al.  CB1 Receptor Blockade and its Impact on Cardiometabolic Risk Factors: Overview of the RIO Programme with Rimonabant , 2008, Journal of neuroendocrinology.

[5]  Nick Finer,et al.  Management of Obesity in Adults: European Clinical Practice Guidelines , 2008, Obesity Facts.

[6]  C. Apovian,et al.  Obesity surgery: evidence for diabetes prevention/management. , 2008, Journal of the American Dietetic Association.

[7]  W. James The epidemiology of obesity: the size of the problem , 2008, Journal of internal medicine.

[8]  N. Basso,et al.  Safety and Efficacy of Laparoscopic Adjustable Gastric Banding in the Elderly , 2008, Obesity.

[9]  A. Levy Stem Cells, Hormones and Pituitary Adenomas , 2007, Journal of neuroendocrinology.

[10]  Long term pharmacotherapy for obesity and overweight: updated meta-analysis , 2007, BMJ : British Medical Journal.

[11]  D. Lau,et al.  overweight: updated meta-analysis Long term pharmacotherapy for obesity and , 2007 .

[12]  J. Després,et al.  International Day for the Evaluation of Abdominal Obesity (IDEA): A Study of Waist Circumference, Cardiovascular Disease, and Diabetes Mellitus in 168 000 Primary Care Patients in 63 Countries , 2007, Circulation.

[13]  J. Lau,et al.  Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. , 2007, JAMA.

[14]  G. Wittert,et al.  Management of obesity in patients with type 2 diabetes mellitus. , 2007, Current diabetes reviews.

[15]  H Buchwald,et al.  Inter-disciplinary European guidelines on surgery of severe obesity , 2007, International Journal of Obesity.

[16]  M. Jensen,et al.  Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study , 2006, The Lancet.

[17]  Simon Smyth,et al.  Diabetes and obesity: the twin epidemics , 2006, Nature Medicine.

[18]  L. Gaal,et al.  What is the relationship between risk factor reduction and degree of weight loss , 2005 .

[19]  J. Miles,et al.  The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes , 2005, Expert opinion on pharmacotherapy.

[20]  S. Kritchevsky,et al.  Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. , 2005, The American journal of clinical nutrition.

[21]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[22]  T. Harris,et al.  Health consequences of obesity in the elderly: a review of four unresolved questions , 2005, International Journal of Obesity.

[23]  R. Vettor,et al.  Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. , 2005, Diabetes care.

[24]  S. Wannamethee,et al.  Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes , 2005, Journal of Epidemiology and Community Health.

[25]  Claude Bouchard,et al.  Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. , 2004, The New England journal of medicine.

[26]  D. Arterburn,et al.  The Coming Epidemic of Obesity in Elderly Americans , 2004, Journal of the American Geriatrics Society.

[27]  L. Sjöström,et al.  XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. , 2004, Diabetes care.

[28]  Karen C Johnson,et al.  Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. , 2003, Controlled clinical trials.

[29]  From the Centers for Disease Control and Prevention. Public health and aging: trends in aging--United States and worldwide. , 2003, JAMA.

[30]  A. Scheen,et al.  New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. , 2002, Diabetes & metabolism.

[31]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[32]  C. Ritchie,et al.  Sarcopenia, weight loss, and nutritional frailty in the elderly. , 2002, Annual review of nutrition.

[33]  L. Gaal,et al.  The importance of obesity in diabetes and its treatment with sibutramine , 2001, International Journal of Obesity.

[34]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[35]  S. Vale,et al.  Psychoneuroendocrine characteristics of common obesity clinical subtypes , 2001, International Journal of Obesity.

[36]  A. Hofman,et al.  A comparison of body mass index, waist–hip ratio and waist circumference as predictors of all-cause mortality among the elderly: the Rotterdam study , 2001, International Journal of Obesity.

[37]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[38]  F. Pi‐Sunyer Weight loss and mortality in type 2 diabetes. , 2000, Diabetes care.

[39]  M. Thun,et al.  Intentional weight loss and mortality among overweight individuals with diabetes. , 2000, Diabetes care.

[40]  J. Halter,et al.  Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults , 2000, Journal of epidemiology and community health.

[41]  J. Seidell,et al.  Body weight and weight change and their health implications for the elderly , 2000, European journal of clinical nutrition.

[42]  S. Wannamethee,et al.  Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. , 1999, Diabetes care.

[43]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[44]  Uk-Prospective-Diabetes-Study-Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[45]  R. Micciolo,et al.  Effects of age on body fat distribution and cardiovascular risk factors in women. , 1997, The American journal of clinical nutrition.

[46]  R N Pierson,et al.  How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? , 1996, American journal of epidemiology.

[47]  P J Garry,et al.  Cross-sectional age differences in body composition in persons 60+ years of age. , 1995, The journals of gerontology. Series A, Biological sciences and medical sciences.

[48]  H. Nakano,et al.  [Obesity in the elderly]. , 1995, Nihon rinsho. Japanese journal of clinical medicine.

[49]  小谷 一晃 Sexual dimorphism of age-related changes in whole-body fat distribution in the obese , 1994 .

[50]  Y. Matsuzawa,et al.  Sexual dimorphism of age-related changes in whole-body fat distribution in the obese. , 1994, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[51]  P. Garthwaite,et al.  Obesity, Weight Loss and Prognosis in Type 2 Diabetes , 1990, Diabetic medicine : a journal of the British Diabetic Association.

[52]  J. Tobin,et al.  Studies in the distribution of body fat. II. Longitudinal effects of change in weight. , 1989, International journal of obesity.